Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer
Status:
Not yet recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the tolerance of albumin paclitaxel combined with apatinib and
Camrelizumab in the second-line treatment of advanced gastric cancer to determine the maximum
tolerable dose (MTD) of the combination.